Mineralys says Phase 3 Launch-HTN trial shows 46% of lorundrostat patients hit SBP target below 130 mmHg at week 12

• Mineralys Therapeutics presented new analyses on lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026.
• Launch-HTN pivotal trial analysis showed many difficult-to-treat hypertension patients reached guideline blood-pressure goals or achieved meaningful reductions.
• Explore-OSA Phase 2 results showed morning blood-pressure reductions in obese adults with sleep apnea, without improving sleep-apnea severity measures.
• Safety profile looked favorable across the sleep-apnea study, with no signal of major potassium-related concerns.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610090900PRIMZONEFULLFEED9842685) on October 09, 2026, and is solely responsible for the information contained therein.